A Master Protocol for a Phase 2 Randomized, Double-blind, Placebo-controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies against Factor XI for Prevention of Venous Thromboembolism in Patients with a Peripherally Inserted Central Catheter (ROXI-CATH).

Venous Thromboembolism

Incidence of confirmed VTE per central reading center (CRC) review, Incidence and severity of treatment-emergent adverse events (TEAE)

Incidence of confirmed PICC-associated venous thrombosis per CRC review, Incidence of major bleeding and clinically relevant non-major (CRNM) bleeding, Concentrations of REGN9933, Concentrations of REGN7508, Change in activated partial thromboplastin time (aPTT) and in prothrombin time (PT), Incidence and magnitude of anti-drug antibodies (ADA) to REGN9933 over time, Incidence and magnitude of ADA to REGN7508 over time

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Bulgaria, Romania, Spain